Merck Stock News

It's not all smooth sailing for this drugmaker.

Sector ETF report for RYH

MANILA — The Philippines has approved the emergency use of Paxlovid, Pfizer’s PFE.N COVID-19 drug, the country’s food and drug agency said on Friday. It is the third COVID-19 drug approved by the agency for emergency use, after Roche’s ROG.S antibody cocktail and Merck & Co Inc’s MRK.N treatment pill. Paxlovid can be used to treat […] The post FDA approves emergency use of Pfizer’s COVID-19 drug Paxlovid appeared first on Interaksyon .

MANILA: The Philippines has approved the emergency use of Paxlovid, Pfizer’s COVID-19 drug, the country’s food and drug agency said on Friday. It is the third COVID-19 drug approved by the agency for emergency use, after Roche’s antibody cocktail and Merck & Co Inc’s treatment pill. Pfizer begins COVID pill study in high-risk children aged 6-17 Paxlovid can be used to treat adult patients who do not require supplemental oxygen and who are at increased risk for severe infection, the agency said.

Merck (MRK) closed at $77.89 in the latest trading session, marking a +0.13% move from the prior day.

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), Qualcomm Inc. (QCOM) and ConocoPhillips (COP).

CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1 st cohort fully enrolled siRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studies THR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemia Multiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvir Merck expanded the NASH research collaboration utilizing Aligos’ proprietary oligonucleotide technology

Almost a thousand patients in Cyprus have been administered Molnupiravir, the antiviral medication for COVID, said Deputy head of pharmaceutical services Elena Panagiotopoulou. Merck anti-Covid oral pill Molnupiravir /Lagevrio 200mg has been administered to 984 patients, and only 7% of them had to be admitted to the hospital. She told the Cyprus News Agency no deaths or any side-effects were reported. Panagiotopoulou said that authorities could not draw safe conclusions regarding the drug’s efficacy. This is only possible if, at the same time this medication was given, a placebo drug was given to an equal number of patients. She explained The post COVID19: Molnupiravir pill administered to 1,000 patients appeared first on Financial Mirror .

Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.

On CNBC’s “Halftime Report Final Trades,” Brenda Vingiello of Sand Hill Global Advisors said Sherwin-Williams Co’s (NYSE: SHW) stock has lost 30% year-to-date and the company is “very well p

On CNBC’s “ Halftime Report Final Trades ,” Brenda Vingiello of Sand Hill Global Advisors said Sherwin-Williams Co’s (NYSE: SHW ) stock has lost 30% year-to-date and the company is “very well positioned.” The news of higher input costs is “already out” and Sherwin-Williams “should have higher volumes as a result of a really healthy market,” she … Full story available on Benzinga.com

Smart Beta ETF report for RYH

There high-quality healthcare stocks are at fire-sale prices today.

The CIS Insulin report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a

J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.